Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
Question
Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
Direct answer
Expanding prescription volume for targeted biologics directly drives multi-year top-line franchise growth for REGN and ABBV. — bullish pressure on ABBV via immunology portfolio volume growth.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-06
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics”, revision 1, evidence through 2026-09-06. https://marketontology.com/catalysts/2026-09-06/atopic-dermatitis-therapeutic-market-projected-to-reach-33-42b-by-2035-on-biolog-5f6efc
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ABBV | ▲Bull | 1–3 months | immunology portfolio volume growth | 62 |
Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
Expanding prescription volume for targeted biologics directly drives multi-year top-line franchise growth for REGN and ABBV. — bullish pressure on ABBV via immunology portfolio volume growth.
AbbVie identified as major participant in dermatology biologics and JAK inhibitors
- SourceAbbVie identified as major participant in dermatology biologics and JAK inhibitors
- TransmissionExpanding prescription volume for targeted biologics directly drives multi-year top-line franchise growth for REGN and ABBV.
- SummaryIndustry data projects the atopic dermatitis market to more than double from $15.92B in 2025 to $33.42B by 2035. North America retains the largest share at 36%, driven by high-cost biologic penetration and novel JAK inhibitors. Key pharmaceutical developers include Regeneron, AbbVie, Eli Lilly, and Sanofi.
- ABBVDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- ABBV closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ABBV price vs. pre-event level
- ABBV volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - SNS Insider · media · 2026-09-05
Related catalysts
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-09-21Bristol Myers Squibb growth portfolio hits 60% of revenue after Q2 profit surgeABBV BMY
- 2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surgeABBV BMY
- 2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS SurgeABBV BMY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.